Table 1 Physician and nurse characteristics
From: Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews
Characteristic, n (%) | Physicians/Nurses (n = 25) |
|---|---|
Sex | |
Male | 10 (40%) |
Female | 15 (60%) |
Age, years | |
Median (range) | 44 (28–68) |
< 40 | 10 (40%) |
40–60 | 12 (48%) |
> 60 | 3 (12%) |
Study centres | |
Melanoma Centre 1 | 14 (56%) |
Melanoma Centre 2 | 3 (12%) |
Melanoma Centre 3 | 8 (32%) |
Healthcare speciality | |
Medical Oncologista | 11 (44%) |
Surgeon | 8 (32%) |
Dermatologist | 1 (4%) |
Clinical Nurse Consultant/Clinical Trials Managerb | 5 (20%) |
Hours worked per week | |
< 50 | 8 (32%) |
50–60 | 16 (64%) |
> 60 | 1 (4%) |
Years since completing specialist medical/nursing training | |
< 10 | 11 (44%) |
10–20 | 8 (32%) |
> 20 | 6 (24%) |
Years experience treating melanoma | |
< 10 | 9 (36%) |
10–20 | 11 (44%) |
> 20 | 5 (20%) |
% of patients seen with melanoma | |
< 50 | 6 (24%) |
50–75 | 5 (20%) |
> 75 | 14 (56%) |
Average number of stage III patients eligible for adjuvant immunotherapy seen per month | |
< 5 | 12 (48%) |
5–15 | 11 (44%) |
> 15 | 2 (8%) |
% of physicians and nurses by speciality recommending immunotherapy clinical trials for stage II patientsc | |
Medical Oncologista | 9 (36%) |
Surgeon | 6 (24%) |
Dermatologist | 1 (4%) |
Clinical Nurse Consultant | 4 (16%) |